Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322217 · ClinicalTrials.gov registry record
Managerial Database II
A clinical trial of Acquired Immunodeficiency Syndrome, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 513
- Enrollment target
- 5
- Study locations
NCT01322217: Completed study of Acquired Immunodeficiency Syndrome, sponsored by University of North Carolina, Chapel Hill.
NCT01322217 is a study of Acquired Immunodeficiency Syndrome that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 513 participants, above the 187-participant average among 17 other Acquired Immunodeficiency Syndrome trials with a reported enrollment target (174% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01322217, a study of Acquired Immunodeficiency Syndrome, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 513 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will collect information on health status and risk behaviors, as well as basic demographic and biomedical information for a group of HIV positive adolescents receiving care at sites newly participating in ATN III.
Primary Outcome
Collect information on rates of adherence to medical regimens, sexual risk behavior, substance use and mental health concerns, along with basic demographic and biomedical data for adolescents and young adults with HIV infection engaged in care at the AMTUs to better understand the extent of risk behaviors as well as to understand risk and protective factors in this population.
Conditions Studied
Study Locations (5)
Colorado
- University of Colorado Denver - Aurora
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- The Fenway Institute-Fenway Health - Boston
Michigan
- Wayne State University-Children's Hospital of Michigan - Detroit
Texas
- Baylor College of Medicine - Pediatrics Allergy and Immunology - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 513 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-06 |
What the finished NCT01322217 record still lists
NCT01322217 is an observational study that tracks outcomes without assigning an intervention. The registered 513 participants enrollment target is mid-sized for trials with a published cap, above the 187-participant average among 17 other Acquired Immunodeficiency Syndrome trials with a reported enrollment target (174% higher).
The record links to 1 condition, with Acquired Immunodeficiency Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT01322217 lists 5 locations in 5 states (Colorado, Maryland, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT01322217 about?
NCT01322217 is a clinical study titled "Managerial Database II". This study will collect information on health status and risk behaviors, as well as basic demographic and biomedical information for a group of HIV positive adolescents receiving care at sites newly participating in ATN III.
What is the current status of trial NCT01322217?
This trial is currently completed. The enrollment target is 513 participants. The study started on 2011-04. Estimated completion is 2012-06.
What conditions does trial NCT01322217 study?
This clinical trial studies the following conditions: Acquired Immunodeficiency Syndrome.
Who is sponsoring clinical trial NCT01322217?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01322217 being conducted?
This trial has 5 study locations across Colorado, Maryland, Massachusetts, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acquired Immunodeficiency Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01322217's enrollment target sits among peer trials
513 3rd of 17 higher than 15 of 17 other Acquired Immunodeficiency Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acquired Immunodeficiency Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
ACTIVE NOT RECRUITING · Phase 1
-
Twins Study of Gene Therapy for HIV Infection
COMPLETED · Phase 1
-
Mesalamine to Reduce T Cell Activation in HIV Infection
COMPLETED · Phase 4
-
HIV Prevention Intervention for Couples
COMPLETED · Phase 2
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
- NCT06585488 · 514 participants · Phase 1
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
- NCT06716606 · 514 participants · Phase 3
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
- NCT05005403 · 512 participants · Phase 1
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia